The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

PubWeight™: 2.18‹?› | Rank: Top 2%

🔗 View Article (PMC 2856332)

Published in Respir Med on October 07, 2009

Authors

Jeffrey J Swigris1, Kevin K Brown, Juergen Behr, Roland M du Bois, Talmadge E King, Ganesh Raghu, Frederick S Wamboldt

Author Affiliations

1: Interstitial Lung Disease Program in the Autoimmune Lung Center and Division of Psychosocial Medicine, National Jewish Health, Denver, CO, USA. swigrisj@njc.org

Associated clinical trials:

Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis. (PALIF) | NCT03229343

Articles citing this

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J (2015) 1.65

A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest (2014) 1.37

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis (2011) 1.25

Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax (2013) 1.14

Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest (2013) 1.05

The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis (2013) 0.93

Gender influences Health-Related Quality of Life in IPF. Respir Med (2009) 0.92

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res (2014) 0.89

St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis. Chest (2013) 0.89

Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest (2013) 0.89

Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest (2012) 0.88

Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res (2012) 0.88

The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87

Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest (2012) 0.86

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther (2013) 0.83

Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J (2011) 0.80

New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79

Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung (2015) 0.79

A dance intervention for cancer survivors and their partners (RHYTHM). J Cancer Surviv (2017) 0.77

Older adults with chronic lung disease report less limitation compared with younger adults with similar lung function impairment. Ann Am Thorac Soc (2015) 0.77

B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PLoS One (2014) 0.76

The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res (2017) 0.75

The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancer. Qual Life Res (2017) 0.75

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Can Respir J (2016) 0.75

Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res (2016) 0.75

Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75

Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas (2016) 0.75

Telehealthcare for patients suffering from chronic obstructive pulmonary disease: effects on health-related quality of life: results from the Danish 'TeleCare North' cluster-randomised trial. BMJ Open (2017) 0.75

Articles cited by this

The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care (2003) 19.69

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med (2002) 19.02

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71

The St George's Respiratory Questionnaire. Respir Med (1991) 8.49

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19

Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol (1999) 4.90

St. George's Respiratory Questionnaire: MCID. COPD (2005) 3.99

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum (2000) 3.64

Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care (1999) 3.57

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49

What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes (2003) 3.42

Health status measurement in chronic obstructive pulmonary disease. Thorax (2001) 3.07

Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD (2005) 2.85

The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes (2008) 2.07

Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J (2003) 1.84

Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64

Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51

Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest (2005) 1.36

Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. Intern Med (2007) 1.14

Analysis of a life satisfaction index. J Gerontol (1969) 0.88

Articles by these authors

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62

High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82

Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74

Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51

A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02

Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94

Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88

Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33

Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85

Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25

The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25

The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15

Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85

Sarcoidosis. Lancet (2003) 3.60

Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45

Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37

Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21

Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06

Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05

Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00

Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97

A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92

Pulmonary fibrosis associated with aluminum trihydrate (Corian) dust. N Engl J Med (2014) 2.88

Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74

Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69

Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66

Family asthma management routines: connections to medical adherence and quality of life. J Pediatr (2005) 2.66

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65

Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62

Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54

A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54

Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51

Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50

Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43

Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42

Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40

Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34

Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.32

Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20

Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One (2010) 2.19